Recent Quotes (30 days)

You have no recent quotes
chg | %

Theratechnologies Inc  

(Public, TSE:TH)   Watch this stock  
Find more results for TH
6.94
+0.24 (3.58%)
May 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.70 - 7.02
52 week 2.33 - 7.02
Open 6.75
Vol / Avg. 182,546.00/152,813.00
Mkt cap 524.16M
P/E     -
Div/yield     -
EPS -0.02
Shares 73.84M
Beta 1.12
Inst. own     -
May 16, 2017
Theratechnologies Inc at CIBC Technology & Innovation Conference
May 2, 2017
Theratechnologies Inc at Bloom Burton & Co. Healthcare Investor Conference
Apr 6, 2017
Theratechnologies Inc at Laurentian Bank Securities Institutional Investor Conference
Apr 6, 2017
Q1 2017 Theratechnologies Inc Earnings Call
Mar 31, 2017
Q1 2017 Theratechnologies Inc Earnings Release (Estimated)
  

Key stats and ratios

Q1 (Feb '17) 2016
Net profit margin -24.83% 1.11%
Operating margin -0.40% 10.62%
EBITD margin - 16.31%
Return on average assets -14.73% 0.80%
Return on average equity -26.95% 1.75%
Employees 26 -
CDP Score - -

Address

2015 Peel St 5th Floor
MONTREAL, QC H3A 1T8
Canada
+1-514-3367800 (Phone)
+1-514-3319691 (Fax)

Website links

Description

Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

Officers and directors

Dawn Svoronos Independent Chairman of the Board
Age: 62
Luc Tanguay President, Chief Executive Officer, Director
Age: 57
Philippe Dubuc Chief Financial Officer, Senior Vice President
Lyne Fortin Senior Vice President, Chief Commercial Officer
Christian Marsolais Ph.D. Senior Vice President - Scientific Affairs and Alliances
Age: 52
Marie-Noel Colussi Vice President - Finance
Age: 46
Jocelyn Lafond Vice President - Legal Affairs, Corporate Secretary
Age: 48
Pierre Perazzelli Vice President - Pharmaceutical Development
Age: 63
Dale Weil Director
Gilles Cloutier Ph.D. Independent Director
Age: 70